First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis
Year: 2025
Type: article
Study design: Clinical Trial
Source: Molecular Cancer Therapeutics
Institution: Renmin Hospital of Wuhan University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: apatinib, tislelizumab, advanced gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, signet ring cell carcinoma, peritoneal carcinomatosis, HER2-negative, immune checkpoint inhibitors, combination chemotherapy, maintenance therapy, progression-free survival, objective response rate, health-related quality of life, adverse events
Open Access status: closed
OpenAlex ID: W4407082102
